IL327385A - Rock2 inhibitors in the treatment of obesity - Google Patents

Rock2 inhibitors in the treatment of obesity

Info

Publication number
IL327385A
IL327385A IL327385A IL32738526A IL327385A IL 327385 A IL327385 A IL 327385A IL 327385 A IL327385 A IL 327385A IL 32738526 A IL32738526 A IL 32738526A IL 327385 A IL327385 A IL 327385A
Authority
IL
Israel
Prior art keywords
obesity
treatment
rock2 inhibitors
rock2
inhibitors
Prior art date
Application number
IL327385A
Other languages
Hebrew (he)
Original Assignee
Graviton Pharmaceuticals B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Graviton Pharmaceuticals B V filed Critical Graviton Pharmaceuticals B V
Publication of IL327385A publication Critical patent/IL327385A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL327385A 2023-09-29 2024-09-30 Rock2 inhibitors in the treatment of obesity IL327385A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363586921P 2023-09-29 2023-09-29
PCT/IB2024/059568 WO2025069009A1 (en) 2023-09-29 2024-09-30 Rock2 inhibitors in the treatment of obesity

Publications (1)

Publication Number Publication Date
IL327385A true IL327385A (en) 2026-05-01

Family

ID=93257864

Family Applications (1)

Application Number Title Priority Date Filing Date
IL327385A IL327385A (en) 2023-09-29 2024-09-30 Rock2 inhibitors in the treatment of obesity

Country Status (3)

Country Link
AU (1) AU2024352974A1 (en)
IL (1) IL327385A (en)
WO (1) WO2025069009A1 (en)

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005723A1 (en) 1988-11-24 1990-05-31 Yoshitomi Pharmaceutical Industries, Ltd. Trans-4-amino(alkyl)-1-pyridylcarbamoyl-cyclohexane compounds and their medicinal use
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP3149958B2 (en) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ GLP-1 derivative
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
US6127263A (en) 1998-07-10 2000-10-03 Applied Materials, Inc. Misalignment tolerant techniques for dual damascene fabrication
SI1180121T1 (en) 1999-05-17 2004-04-30 Conjuchem, Inc. Long lasting insulinotropic peptides
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
AU2001273233A1 (en) 2000-07-06 2002-01-21 Deltagen, Inc. Transgenic mice containing cx2 gene disruptions
JP4629047B2 (en) 2003-06-12 2011-02-09 イーライ リリー アンド カンパニー GLP-1 analog complex protein
JP4764823B2 (en) 2003-10-06 2011-09-07 グラクソ グループ リミテッド Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors
JP4857128B2 (en) 2004-02-20 2012-01-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー New compounds
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
CR9465A (en) 2005-03-25 2008-06-19 Surface Logix Inc PHARMACOCINETICALLY IMPROVED COMPOUNDS
PL1905452T3 (en) 2005-07-12 2013-11-29 Kowa Co Agent for prevention or treatment of glaucoma
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
EP2406236A4 (en) * 2009-03-09 2013-07-24 Surface Logix Inc INHIBITORS OF RHO KINASE
WO2011130740A2 (en) 2010-04-16 2011-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pyridylthiazole-based ureas as inhibitors of rho associated protein kinase (rock) and methods of use
ES2606554T3 (en) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the manufacture of a medication for the treatment of type 2 diabetes mellitus
EP2903618B1 (en) 2012-10-05 2022-06-01 Kadmon Corporation, LLC Rho kinase inhibitors
WO2015157556A1 (en) 2014-04-09 2015-10-15 Kadmon Corporation, Llc Treatment of gvhd
JO3575B1 (en) 2015-01-09 2020-07-05 Lilly Co Eli Gip and glp-1 co-agonist compounds
JOP20190060A1 (en) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd Pyrazolopyridine derivative having glp-1 receptor agonist effect
AU2020273376C1 (en) * 2016-10-24 2024-02-29 Translational Drug Development, Llc Amide compounds as kinase inhibitors, compositions and methods of treatment
CN110325530B (en) 2016-12-16 2022-01-11 辉瑞大药厂 GLP-1 receptor agonists and uses thereof
WO2019000683A1 (en) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho-associated protein kinase inhibitor, pharmaceutical composition containing rho-associated protein kinase inhibitor, preparation method and use of the pharmaceutical composition
AU2018294054B2 (en) 2017-06-30 2022-05-26 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
CN110573501B (en) 2017-06-30 2023-09-29 北京泰德制药股份有限公司 Rho-related protein kinase inhibitors, pharmaceutical compositions containing the same and preparation methods and uses thereof
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
WO2019194598A1 (en) * 2018-04-05 2019-10-10 서울대학교산학협력단 Rock2 inhibitor as skeletal muscle metabolic activator for improvement of obesity and diabetes
WO2020142745A1 (en) * 2019-01-04 2020-07-09 Translational Drug Development, Llc Methods of treating graft versus host disease and neoplastic disease with amide compounds
US12398118B2 (en) 2018-11-09 2025-08-26 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and use thereof
KR102906316B1 (en) 2019-03-01 2025-12-31 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Treatment of fatty liver disease and/or steatohepatitis
CA3144113A1 (en) 2019-06-25 2020-12-30 Beijing Tide Pharmaceutical Co., Ltd. Method for treating idiopathic pulmonary fibrosis
CA3168543A1 (en) * 2020-01-29 2021-08-05 Gilead Sciences, Inc. Glp-1r modulating compounds
CN118772118A (en) 2020-08-31 2024-10-15 北京泰德制药股份有限公司 Salts of Rho-associated protein kinase inhibitors, solid forms thereof, and preparation methods and uses thereof
KR20230058466A (en) 2020-08-31 2023-05-03 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Methods for preparing novel RHO-associated protein kinase inhibitors and intermediates in manufacturing methods
US20220193063A1 (en) 2020-12-15 2022-06-23 Pfizer Inc. Metabolites of glp1r agonists
WO2022192430A1 (en) * 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
US20220348564A1 (en) 2021-03-24 2022-11-03 Eccogene (Shanghai) Co., Ltd. Phenyl-[1,3]dioxolo[4,5-c]pyridinyl-phenyl-, phenyl-[1,3]dioxolo[4,5-c]pyridinyl-heteroaryl-, or phenyl-(1,3)dioxo[4,5-c]pyridinyl-piperidinyl-methyl-oxetanylmethyl-1h-benzo[d]imidazole-carboxylic acid derivatives and methods of using same
CA3231781A1 (en) * 2021-09-18 2023-03-23 Beijing Tide Pharmaceutical Co., Ltd. Solid form of rho-associated protein kinase inhibitor or solvate thereof, preparation method and use thereof
US11779588B2 (en) * 2021-10-15 2023-10-10 Woolsey Pharmaceuticals, Inc. Method of treating amyotrophic lateral sclerosis
US20250289807A1 (en) 2022-04-29 2025-09-18 Graviton Bioscience Bv Inhibitors of ROCK2
AU2023386016A1 (en) 2022-11-21 2025-06-19 Graviton Bioscience Bv Inhibitors of rock2

Also Published As

Publication number Publication date
AU2024352974A1 (en) 2026-05-14
WO2025069009A1 (en) 2025-04-03

Similar Documents

Publication Publication Date Title
IL308195A (en) Ras inhibitors for the treatment of cancer
PT4181920T (en) Kat6 inhibitor methods and combinations for cancer treatment
IL288395A (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
PH12021552856A1 (en) Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
IL307883A (en) Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy
ZA202307970B (en) Compounds for use in the treatment and prevention of covid- 19
IL310209A (en) Rock2 inhibitors and uses thereof
IL289758A (en) Proportin inhibitors for use in the prevention and treatment of kidney damage
IL316829A (en) Menin-mll inhibitors for the treatment of cancer
IL276668A (en) Thioredoxin reductase inhibitors for use in the treatment of cancer
IL321393A (en) Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer
SMT202500434T1 (en) Sotorasib for use in the treatment of cancer
SI3969000T1 (en) Bcl-2 inhibitors for use in the treatment of a bcl-2 mediated cancer carrying the gly101val mutation
EP4193995A4 (en) Use of btk inhibitors in the treatment of diseases
AU2024352974A1 (en) Rock2 inhibitors in the treatment of obesity
CA3305450A1 (en) Rock2 inhibitors in the treatment of obesity
IL318816A (en) Mta-cooperative prmt5 inhibitors for use in the treatment of cancer
PL4346847T3 (en) Pluri-ionic complex for use in the prevention or treatment of neurogenic inflammation
IL319049A (en) Tyk2 inhibitors and uses thereof
GB202002299D0 (en) Agents for use in the treatment of tissue damage
HK40090075A (en) Cilp-1 inhibitors for use in the treatment of dilated cardiomyopathies
IL290328A (en) Monoamine oxidase b inhibitors for use in the prevention or treatment of prostate carcinoma
IL327100A (en) Elsunersen / prax-222 for use in the treatment of scn2a-related disorders
HK40081983A (en) Cxcl8 inhibitors for use in the treatment of covid-19
IL319889A (en) Tasipimidine and cyp2d6 inhibitor combination treatment